These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16400743)

  • 1. Duloxetine: new drug. For stress urinary incontinence: too much risk, too little benefit.
    Prescrire Int; 2005 Dec; 14(80):218-20. PubMed ID: 16400743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects.
    Prescrire Int; 2006 Oct; 15(85):168-72. PubMed ID: 17121211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine versus placebo in the treatment of stress urinary incontinence.
    Norton PA; Zinner NR; Yalcin I; Bump RC;
    Am J Obstet Gynecol; 2002 Jul; 187(1):40-8. PubMed ID: 12114886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.
    Mariappan P; Ballantyne Z; N'Dow JM; Alhasso AA
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004742. PubMed ID: 16034945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.
    van Kerrebroeck P; Abrams P; Lange R; Slack M; Wyndaele JJ; Yalcin I; Bump RC;
    BJOG; 2004 Mar; 111(3):249-57. PubMed ID: 14961887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.
    Millard RJ; Moore K; Rencken R; Yalcin I; Bump RC;
    BJU Int; 2004 Feb; 93(3):311-8. PubMed ID: 14764128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Place of duloxetine in the treatment of stress urinary incontinence].
    Rouprêt M; Richard F; Chartier-Kastler E
    Prog Urol; 2005 Sep; 15(4):689-92. PubMed ID: 16459687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence.
    Cardozo L; Lange R; Voss S; Beardsworth A; Manning M; Viktrup L; Zhao YD
    Curr Med Res Opin; 2010 Feb; 26(2):253-61. PubMed ID: 19929591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment of women awaiting surgery for stress urinary incontinence.
    Cardozo L; Drutz HP; Baygani SK; Bump RC
    Obstet Gynecol; 2004 Sep; 104(3):511-9. PubMed ID: 15339761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine: a new approach for treating stress urinary incontinence.
    Moore K
    Int J Gynaecol Obstet; 2004 Jul; 86 Suppl 1():S53-62. PubMed ID: 15302567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and adverse event profile of duloxetine.
    Wernicke JF; Gahimer J; Yalcin I; Wulster-Radcliffe M; Viktrup L
    Expert Opin Drug Saf; 2005 Nov; 4(6):987-93. PubMed ID: 16255658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence.
    Schagen van Leeuwen JH; Lange RR; Jonasson AF; Chen WJ; Viktrup L
    Maturitas; 2008 Jun; 60(2):138-47. PubMed ID: 18547757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence.
    Dmochowski RR; Miklos JR; Norton PA; Zinner NR; Yalcin I; Bump RC;
    J Urol; 2003 Oct; 170(4 Pt 1):1259-63. PubMed ID: 14501737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review.
    Mariappan P; Alhasso A; Ballantyne Z; Grant A; N'Dow J
    Eur Urol; 2007 Jan; 51(1):67-74. PubMed ID: 17014950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of Duloxetine in the treatment of male stress urinary incontinence.
    Fink KG; Huber J; Würnschimmel E; Schmeller NT
    Wien Med Wochenschr; 2008; 158(3-4):116-8. PubMed ID: 18330528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence.
    Castro-Diaz D; Palma PC; Bouchard C; Haab F; Hampel C; Carone R; Zepeda Contreras S; Rodriguez Ginorio H; Voss S; Yalcin I; Bump RC;
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Aug; 18(8):919-29. PubMed ID: 17160693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine for management of stress urinary incontinence.
    Guay DR
    Am J Geriatr Pharmacother; 2005 Mar; 3(1):25-38. PubMed ID: 16089245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Duloxetine. A new preparation for patients with urinary incontinence].
    Walter S
    Ugeskr Laeger; 2005 Nov; 167(48):4553-5. PubMed ID: 16324435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of duloxetine in women with stress urinary incontinence.
    Bump RC; Voss S; Beardsworth A; Manning M; Zhao YD; Chen W
    BJU Int; 2008 Jul; 102(2):214-8. PubMed ID: 18422764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations).
    Weinstein DL; Cohen JS; Liu C; Meadows ES; Plouffe L; Muram D;
    Curr Med Res Opin; 2006 Nov; 22(11):2121-9. PubMed ID: 17076972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.